SCHEMBL2082379

SCHEMBL2082379

CCOC(=O)c1cn([C@@H]2C[C@H]2F)c2c(C)c(F)ccc2c1=O

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.45
CYP3A4 P08684 1/20 0.43
ADRB2 P07550 1/20 0.42
CNR1 P21554 1/20 0.42
CNR2 P34972 1/20 0.42
HTT P42858 1/20 0.42
KMT2A Q03164 3/20 0.41
STAT3 P40763 2/20 0.40
ALDH1A1 P00352 3/20 0.39
HPGD P15428 3/20 0.39
KDM4E B2RXH2 2/20 0.39
HSD17B10 Q99714 2/20 0.39
LMNA P02545 1/20 0.39
MEN1 O00255 2/20 0.38
MAPT P10636 1/20 0.38
THRB P10828 1/20 0.38
PKM P14618 1/20 0.37
TSHR P16473 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2082380 1.00 TDP1 (0.45) TDP1CYP3A4ADRB2CNR1CNR2
SCHEMBL9145403 0.91 ADRB2 (0.47) TDP1CYP3A4ADRB2CNR1CNR2
SCHEMBL9145398 0.91 ADRB2 (0.47) TDP1CYP3A4ADRB2CNR1CNR2
SCHEMBL9148480 0.89 TDP1 (0.43) TDP1CYP3A4ADRB2CNR1CNR2
SCHEMBL9149546 0.89 TDP1 (0.43) TDP1CYP3A4ADRB2CNR1CNR2
SCHEMBL9148485 0.89 TDP1 (0.43) TDP1CYP3A4ADRB2CNR1CNR2
SCHEMBL2080449 0.89 CYP3A4 (0.49) TDP1CYP3A4ADRB2CNR1CNR2
SCHEMBL2080448 0.89 CYP3A4 (0.49) TDP1CYP3A4ADRB2CNR1CNR2
SCHEMBL2082038 0.87 STAT3 (0.50) TDP1CYP3A4ADRB2CNR1CNR2
SCHEMBL2082040 0.87 STAT3 (0.50) TDP1CYP3A4ADRB2CNR1CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7902226-B2 Dehalogeno-compounds DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2011-03-08 US disclosed
EP-1336611-B1 DEHALOGENO COMPOUNDS DAIICHI SEIYAKU CO (JP) 2007-09-05 EP disclosed
US-20070123560-A1 Dehalogeno-compounds DAIICHI PHARMACEUTICAL CO., LTD. 2007-05-31 US disclosed
US-20040063754-A1 Dehalogeno compounds DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-04-01 US disclosed
EP-1336611-A1 DEHALOGENO COMPOUNDS DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2003-08-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040063754-A1 Dehalogeno compounds DEK, PGLS, RPS27L TDP1 3606/4885CYP3A4 198/4885ADRB2 3952/4885
US-20070123560-A1 Dehalogeno-compounds DEK, RPS27L, POLL TDP1 3358/4885CYP3A4 277/4885ADRB2 4090/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.